AI Article Synopsis

Article Abstract

A woman with Philadelphia chromosome-positive c-ALL with +8 and i17q in addition underwent an unpurged blood stem cell autograft after 200mg/m2 melphalan in first relapse. Maintenance therapy with 6-mercatopurine was started following the autograft. Moderate pancytopenia developed after 4 months, and myelodysplasia (refractory anemia) was diagnosed which rapidly evolved into AML. The cytogenetic findings remained unchanged. She also developed CNS disease, but the blasts in the cerebrospinal fluid were lymphoid in character on immunophenotyping. She then received palliative treatment until death. The remarkable features here are the evolution into myelodysplasia and AML with retention of the original complex karyotype, and subsequent coexistence of lymphoid disease in the CNS and myeloid disease systemically. It is possible that the lineage switch and development of myelodysplasia in this case may have been secondary to treatment, but persistence of the original cytogenetic clone makes this unlikely. This may have been the result of some unusual effect of the treatment on the original clone, or expansion of a small unidentified myeloid clone present originally which gained a proliferative advantage due to the ALL-type treatment. This case confirms the aggressive and polymorphic nature of Ph+ ALL which may be the result of origin from an early progenitor cell (stem cell disease).

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428199709050900DOI Listing

Publication Analysis

Top Keywords

development myelodysplasia
8
stem cell
8
sequential development
4
myelodysplasia
4
myelodysplasia acute
4
acute myeloid
4
myeloid leukemia
4
leukemia karyotypic
4
karyotypic evolution
4
evolution autografting
4

Similar Publications

CPX-351 (NS-87; Vyxeos®) has a characteristic liposomal formulation and contains cytarabine and daunorubicin at a 5:1 molar ratio, which demonstrates synergistic activity in both in vitro and in vivo animal models. It has been approved in several countries for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Since there are very few Asian patients, especially Japanese adult and pediatric patients, only a small clinical study has been conducted in Japanese adult patients and no study in Japanese pediatric patients.

View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) is a malignancy of the bone marrow with a median age at diagnosis of 70 years. AML is difficult to treat, especially in older patients, among whom outcomes have historically been poor. Over the last two decades, a greater understanding of the molecular mechanisms of the pathology has led to the development of new drugs and multiple updates to treatment guidelines.

View Article and Find Full Text PDF

Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR): Cytogenetic Abnormalities and Gene Mutations.

J Assoc Genet Technol

January 2024

The International Circle of Genetic Studies Project.

Acute myeloid leukemia, myelodysplasia-related (AML-MR) is a particularly aggressive and adverse subtype of acute myeloid leukemia, predominantly affecting older adults who often face complex treatment challenges and poor prognoses. The majority of AML-MR patients fail to achieve remission, leading to significantly reduced overall survival rates. In light of these dire outcomes, staying informed about the most recent advancements in AML-MR research and clinical practice is imperative.

View Article and Find Full Text PDF

Background: Both cigarette smoking (CGS), through its role as a benzene source, and some metabolic detoxyfiying enzymes (EDTOX) polymorphisms that hamper its inactivation, are considered as risk factors for the development of myelodysplastic neoplasms (MDS) and related disorders. This study aims to confirm such associations.

Patients And Methods: We recruited 61 patients diagnosed with MDS following FAB Group criteria and 180 adults without peripheral blood cytopenia, and we analyzed: i) the crude odds-ratio (OR) for MDS between smokers and non-smokers, ii) the crude OR for MDS between homozygous individuals for the mutation NQO1C-T, or harboring deletions in the genes codyfing for GSTM1 y GSTT1, and those who did not show such genotypes, and iii) the OR for MDS between smokers and non-smokers, adjusted for other potential risk factors.

View Article and Find Full Text PDF

Long-term hematopoietic dysfunction in patients with large-scale mitochondrial DNA deletion syndromes.

Pediatr Blood Cancer

January 2025

Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.

Article Synopsis
  • Pearson syndrome (PS) and Kearns-Sayre syndrome (KSS) are mitochondrial DNA deletion syndromes with PS causing severe childhood cytopenia and KSS having later onset without blood-related issues, both sharing a common mitochondrial DNA deletion.
  • A study of 16 patients revealed that 75% had cytopenia, with many needing blood transfusions, and even after achieving transfusion independence, they showed persistent bone marrow (BM) dysfunction.
  • The research highlights that BM dysfunction is a consistent finding in SLSMD syndromes, which raises concerns about potential clonal evolution and chromosome 7 abnormalities, underscoring the need for specialized hematological monitoring for these patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!